MIB1: A Protein Involved in Cellular Homeostasis and Disease (G57534)

Target Name: MIB1

NCBI ID: G57534

MIB1

MIB1: A Protein Involved in Cellular Homeostasis and Disease

MIB1 (Ubiquitin ligase mind bomb) is a protein that plays a crucial role in the regulation of protein degradation in the body. It is a key player in the ubiquitin system, which is responsible for breaking down damaged or unnecessary proteins. MIB1 is also involved in the regulation of cell division and has been linked to a variety of diseases, including cancer.

MIB1 is a 21-kDa protein that is expressed in most tissues of the body. It is composed of a unique protein domain that consists of a catalytic active site, a regulatory domain, and a transmembrane domain. The catalytic active site is the site where MIB1 performs its most critical functions, including the formation of a covalent complex with ubiquitin.

MIB1 functions as a ubiquitin ligase, which means it binds to the protein ubiquitin and facilitates its formation into a ubiquitin-protein complex. This process is essential for the regulation of protein degradation and for the maintenance of cellular homeostasis. MIB1 is also involved in the regulation of cell division, specifically in the G1 phase of the cell cycle.

MIB1 has been linked to a variety of diseases, including cancer. For example, studies have shown that MIB1 is overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases.

In addition to its role in the regulation of protein degradation and cell division, MIB1 is also involved in the regulation of inflammation. Studies have shown that MIB1 is involved in the production of reactive oxygen species (ROS), which can contribute to the development of oxidative stress in response to inflammation.

MIB1 is also involved in the regulation of the immune response. Studies have shown that MIB1 is involved in the regulation of T cell proliferation and that it plays a role in the development of autoimmune diseases.

MIB1 is a potential drug target and has been studied extensively for its potential therapeutic uses. For example, studies have shown that inhibiting MIB1 can be an effective way to treat a variety of diseases, including cancer, inflammation, and autoimmune diseases. Additionally, researchers have also explored the use of MIB1 as a biomarker for the diagnosis and monitoring of disease.

In conclusion, MIB1 is a protein that plays a crucial role in the regulation of protein degradation and cell division in the body. It is involved in the formation of a ubiquitin-protein complex and is also involved in the regulation of inflammation and the immune response. As a result, MIB1 is a potential drug target and could be used as a biomarker for the diagnosis and monitoring of a variety of diseases.

Protein Name: MIB E3 Ubiquitin Protein Ligase 1

Functions: E3 ubiquitin-protein ligase that mediates ubiquitination of Delta receptors, which act as ligands of Notch proteins. Positively regulates the Delta-mediated Notch signaling by ubiquitinating the intracellular domain of Delta, leading to endocytosis of Delta receptors. Probably mediates ubiquitination and subsequent proteasomal degradation of DAPK1, thereby antagonizing anti-apoptotic effects of DAPK1 to promote TNF-induced apoptosis (By similarity). Involved in ubiquitination of centriolar satellite CEP131, CEP290 and PCM1 proteins and hence inhibits primary cilium formation in proliferating cells. Mediates 'Lys-63'-linked polyubiquitination of TBK1, which probably participates in kinase activation

The "MIB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets